April 05, 2022 – Neuro-Onc
For our clinical story, we’d like to highlight the incredible work of one of our newer additions to the Pediatric Neuro-Oncology Program at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Dr. Tabitha...
The DF/HCC Neuro-Oncology Program seeks to improve the standard of care for primary cancers of the central nervous system. Toward this end, the Program fosters laboratory research in surgery, radiation biology, signal transduction, angiogenesis, tumor vaccines, oncolytic viruses, and immunotherapeutics.
Program investigators participate in all the major consortia for brain tumor clinical trials (ABTC, Alliance, RTOG, CERN, BTTC, Ivy Foundation, COG). Scientific activities are supported by a broad portfolio of peer-reviewed research grants from NCI and NINDS including an NCI SPORE grant to develop genetically stratified clinical trials of small molecule signal transduction inhibitors for high-grade adult gliomas. The Program currently has more than 90 members who represent all seven DF/HCC member institutions. Pediatric Oncologists, in particular from Boston Children’s Hospital, are especially well represented within the program as primary cancers of the brain have recently surpassed the leukemias as the number one cause of cancer related death in children.
April 05, 2022 – Neuro-Onc
For our clinical story, we’d like to highlight the incredible work of one of our newer additions to the Pediatric Neuro-Oncology Program at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Dr. Tabitha...
April 05, 2022 – Neuro-Onc
The 2022 Society for Neuro-Oncology Annual Meeting in Boston, MA included some very special presentations organized by our DF/HCC Neuro-Oncology Program.
April 05, 2022 – Neuro-Onc
Congratulations to the following Neuro-Onc members for recent achievements and accolades.